Cellectar Biosciences INC NEW (CLRB) Dividend History

Cellectar Biosciences, Inc. is a biotechnology company focused on the development of targeted cancer therapies using its proprietary phospholipid drug platform. The company specializes in creating novel compounds that deliver therapeutic agents directly to cancer cells, aiming to improve efficacy and reduce side effects. Cellectar's pipeline includes treatments for various oncology indications, leveraging its expertise in phospholipid chemistry and drug delivery technologies.

100 Campus Drive, Florham Park, NJ, 07932
Phone: (608) 441-8120
Website: https://www.cellectar.com

Dividend History

Cellectar Biosciences INC NEW currently does not pay dividends

Company News

  • Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight

    The Waldenstrom macroglobulinemia market is experiencing steady growth driven by advances in targeted therapies, particularly BTK inhibitors. Rising awareness, improved diagnostics, and increasing clinical trials are propelling market expansion, with several emerging drugs showing promise in treating this rare lymphoma.

    GlobeNewswire Inc.
    Featured Companies: MRK NRIX
  • Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why

    Monday, Cellectar Biosciences Inc (NASDAQ:CLRB) announced that iopofosine I 131 combined with external beam radiation therapy (EBRT) was safe and tolerated in a SPORE Grant-supported investigator-initiated Phase 1 trial. The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%). Complete remission was achieved in 64% of patients, with an ORR of 73% (n=11).  Before treatment with iopofosine I 131, six patients had multiple recurrence, and one had metastatic disease. Additionally, the study demonstrated the durability of tumor control with an overall survival of 67% and progression-free survival of 42% at 12 months. Overall, eleven patients (92%) experienced a treatment-related adverse event.  The most common treatment-related adverse events of any ...Full story available on Benzinga.com

    Benzinga
  • Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?

    Here is how Cellectar Biosciences, Inc. (CLRB) and InMode (INMD) have performed compared to their sector so far this year.

    Zacks Investment Research
    Featured Companies: INMD
  • Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week

    5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: ALZN MBIO RSLS XFOR
Page data last updated 07/23/2025 17:06:09 UTC